Comparator: simvastatin

DRUG5 trials

Sponsors

Organon and Co, Merck Sharp & Dohme LLC

Conditions

HypercholesterolemiaMixed DyslipidemiaMixed HyperlipidemiaPrimary Hypercholesterolemia

Phase 3

Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)

CompletedNCT00092157

Organon and CoHypercholesterolemia

Start: 2002-05-01End: 2003-03-04Updated: 2024-08-15

A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)

CompletedNCT00132717

Organon and CoHypercholesterolemia

Start: 2005-01-01End: 2007-06-01Updated: 2024-08-15

Lipid Efficacy Study (0524B-022)(COMPLETED)

CompletedNCT00269217

Merck Sharp & Dohme LLCMixed Hyperlipidemia, Primary Hypercholesterolemia

Start: 2006-01-31End: 2007-01-31Updated: 2017-04-07

MK-0524B Lipid Study (MK-0524B-063)

CompletedNCT00479882

Merck Sharp & Dohme LLCMixed Dyslipidemia, Primary Hypercholesterolemia

Start: 2007-06-15End: 2008-06-16Updated: 2019-02-06

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

CompletedNCT00479388

Merck Sharp & Dohme LLCMixed Dyslipidemia, Primary Hypercholesterolemia

Start: 2007-07-31End: 2008-10-31Updated: 2015-03-10

Related Papers

Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.

2012-06-0114 citations